Heeney remarked that this marks the initial instance of an AI-generated antigen undergoing human trials. He expressed that the technology has been "astonishing all of us" and highlighted its potential, stating it's "incredible what can be achieved with it for the benefit of humankind."
Vaccine created by artificial intelligence is a global first.
Summary
Heeney announced the first human trial of an AI-designed antigen.
The technology is exceeding expectations and demonstrating remarkable capabilities.
Heeney emphasized its potential benefits for humanity's health and well-being.
Share
Bookmark
Newsletter
Loading comments...
More from AI

Two factors limiting Monday's market surge — in addition, Alphabet unveils its new AI chip strategy.

Johns Hopkins surgeon showcases AI advancement that may detect pancreatic cancer ahead of physicians.

Alphabet shares surge following news of a new, more efficient AI chip in development.
